BACKGROUND: There are few reports describing the features of maternal anti-SSA antibody-associated @entity6015 ( @entity6015 ) @entity1 developing @entity11459 ( @entity11459 ). The aim of this study was to describe the clinical features and the outcome of @entity1 with @entity6015 , with or without @entity11459 . METHODS AND RESULTS: Over a 20-year period, 12 consecutive @entity1 diagnosed with maternal anti-SSA antibody-associated @entity6015 were identified. The maternal anti-SSA antibody levels were measured and fetal echocardiographic findings were reviewed. The ratios of the thickness of the endocardium to that of the whole wall of the left ventricle (LE/W) and right ventricle (RE/W) were measured to investigate the degree of endocardial thickening. A total of 7 @entity1 survived (living group) and were not diagnosed as having @entity11459 . The remaining 5 @entity1 died and were diagnosed with @entity11459 during autopsy (dead group). Fetal echocardiography of the @entity1 showed differences in the thickening and hyperintensity of the endocardium. The RE/W value was significantly higher in the dead group than in the living group. The titers of both maternal anti-52-kDa and anti-60-kDa SSA antibodies were high, but showed no significant differences between the 2 @entity1 groups. CONCLUSIONS: @entity11459 was the major negative prognostic factor for @entity6015 . @entity296 , predominantly in the right ventricle, was related to the outcome of @entity6015 associated with @entity11459 .

Fetal echocardiographic assessment of XXXX in maternal anti-SSA antibody-associated complete heart block.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity296 :: ('MESH:D009202', 'Disease') :: ['Myocardial damage'] @entity6015 :: ('MESH:C535758', 'Disease') :: ['congenital complete heart block', 'CCHB'] @entity11459 :: ('MESH:D004695', 'Disease') :: ['EFE', 'endocardial fibroelastosis']
@entity11459 :: (MESH:D004695,Disease) :: ['endocardial fibroelastosis']
